Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
36
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Houvras Yariv | CHIEF MEDICAL OFFICER | 1 | $0 | $0 | 2026-10-01 |
| Bello Akintunde Olatokumbo | Director | 2 | $0 | $0 | 2026-06-11 |
| Curran Daniel J. | Director | 3 | $0 | $0 | 2026-06-11 |
| Xu Yuan | Director | 6 | $0 | $0 | 2026-06-11 |
| ROSS ROBERT W. | Director | 5 | $0 | $0 | 2026-06-11 |
| Brennan Aoife | Director | 3 | $0 | $0 | 2026-06-11 |
| Bonstein Sara | Director | 5 | $0 | $0 | 2026-06-11 |
| Shannon James Samuel | Director | 6 | $92.2K | $0 | 2026-06-11 |
| Blanchard Cheryl R | Director | 1 | $0 | $0 | 2026-04-15 |
| GILEAD SCIENCES, INC. | 10% Owner | 11 | $13.47M | $0 | 2026-02-13 |
| Frankenfield Christopher James | Chief Operating Officer | 31 | $0 | $11.3K | 2026-01-02 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | 20 | $0 | $2.9K | 2026-01-02 |
| Luptakova Katarina | Chief Medical Officer | 20 | $0 | $0 | 2026-01-01 |
| Russo Rene | PRESIDENT AND CEO | 33 | $24.7K | $0 | 2026-01-01 |
| Rossi Christina | Director | 4 | $0 | $0 | 2025-06-11 |
| Clancy Paul J | Director | 6 | $0 | $0 | 2025-06-11 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 2 | $0 | $640 | 2024-02-08 |
| Atlas Venture Associates Opportunity I, L.P. | 10% Owner | 4 | $0 | $3.6K | 2024-01-12 |
| Huber Martin H. Jr. | President of R&D and CMO | 6 | $0 | $0 | 2023-08-16 |
| Heyman Tomas J. | Director | 2 | $0 | $0 | 2023-06-12 |
| English Edward C | PRINCIPAL ACCOUNTING OFFICER | 1 | $0 | $0 | 2023-01-01 |
| Ross Michael Jay | Director | 2 | $0 | $0 | 2022-06-15 |
| Giovine Salvatore | Chief Financial Officer | 2 | $0 | $0 | 2022-02-22 |
| BCIP Life Sciences Associates, LP | 10% Owner | 4 | $410.1K | $0 | 2021-12-10 |
| FIL Ltd | Other | 2 | $0 | $0 | 2021-10-26 |
| FMR LLC | Other | 10 | $0 | $0 | 2021-10-26 |
| SV7 (IMF) GP LLP | 10% Owner | 8 | $0 | $0 | 2021-10-26 |
| SV7 Impact Medicine Fund LP | 10% Owner | 10 | $10.00M | $0 | 2021-10-26 |
| Takeda Ventures, Inc. | 10% Owner | 3 | $0 | $0 | 2021-10-26 |
| Merck KGaA | 10% Owner | 4 | $0 | $0 | 2021-10-26 |
| Atlas Venture Opportunity Fund I, L.P. | 10% Owner | 7 | $3.00M | $0 | 2021-10-26 |
| Rock Springs Capital Master Fund LP | 10% Owner | 5 | $8.00M | $0 | 2021-10-26 |
| RiverVest Venture Fund IV, L.P. | 10% Owner | 5 | $4.00M | $0 | 2021-10-26 |
| Alexandria Venture Investments, LLC | 10% Owner | 2 | $0 | $0 | 2021-10-26 |
| BAY CITY CAPITAL LLC | 10% Owner | 5 | $5.00M | $0 | 2021-10-26 |
| Deerfield Mgmt L.P. | 10% Owner | 6 | $12.40M | $0 | 2021-10-26 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Houvras Yariv | CHIEF MEDICAL OFFICER | A Award deriv | 2026-10-01 | 2026-10-02 | 105,000 | — | $0 | 105,000 | SEC↗ |
| Brennan Aoife | Director | A Award deriv | 2026-06-11 | 2026-06-12 | 5,000 | — | $0 | 5,000 | SEC↗ |
| Bonstein Sara | Director | A Award deriv | 2026-06-11 | 2026-06-12 | 5,000 | — | $0 | 5,000 | SEC↗ |
| ROSS ROBERT W. | Director | A Award deriv | 2026-06-11 | 2026-06-12 | 5,000 | — | $0 | 5,000 | SEC↗ |
| Xu Yuan | Director | A Award deriv | 2026-06-11 | 2026-06-12 | 5,000 | — | $0 | 5,000 | SEC↗ |
| Curran Daniel J. | Director | A Award deriv | 2026-06-11 | 2026-06-12 | 5,000 | — | $0 | 5,000 | SEC↗ |
| Shannon James Samuel | Director | A Award deriv | 2026-06-11 | 2026-06-12 | 5,000 | — | $0 | 5,000 | SEC↗ |
| Bello Akintunde Olatokumbo | Director | A Award deriv | 2026-06-11 | 2026-06-12 | 5,000 | — | $0 | 5,000 | SEC↗ |
| Blanchard Cheryl R | Director | A Award deriv | 2026-04-15 | 2026-04-16 | 10,000 | — | $0 | 10,000 | SEC↗ |
| Shannon James Samuel | Director | P Buy | 2026-03-26 | 2026-03-30 | 5,000 | $8.79 | $43.9K | 10,000 | SEC↗ |
| GILEAD SCIENCES, INC. | 10% Owner | P Buy deriv | 2026-02-13 | 2026-02-17 | 3,739,000 | $0.53 | $1.98M | 40,384,266 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | S Sale | 2026-01-02 | 2026-01-05 | 7,030 | $0.64 | $4.5K | 24,766 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | S Sale | 2026-01-02 | 2026-01-05 | 1,826 | $0.64 | $1.2K | 6,371 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | M Exercise deriv | 2026-01-01 | 2026-01-05 | 44,250 | — | $0 | 88,500 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | M Exercise deriv | 2026-01-01 | 2026-01-05 | 19,375 | — | $0 | 38,750 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | M Exercise deriv | 2026-01-01 | 2026-01-05 | 5,000 | — | $0 | 10,000 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | M Exercise deriv | 2026-01-01 | 2026-01-05 | 16,625 | — | $0 | 33,250 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | M Exercise | 2026-01-01 | 2026-01-05 | 44,250 | — | $0 | 325,422 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | M Exercise | 2026-01-01 | 2026-01-05 | 19,375 | — | $0 | 31,796 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | M Exercise | 2026-01-01 | 2026-01-05 | 5,000 | — | $0 | 8,197 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | M Exercise | 2026-01-01 | 2026-01-05 | 16,625 | — | $0 | 33,250 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | A Award deriv | 2025-12-31 | 2026-01-05 | 1,500,258 | — | $0 | 1,500,258 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | A Award deriv | 2025-12-31 | 2026-01-05 | 668,789 | — | $0 | 668,789 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A Award deriv | 2025-12-31 | 2026-01-05 | 95,221 | — | $0 | 95,221 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | A Award deriv | 2025-12-31 | 2026-01-05 | 451,885 | — | $0 | 451,885 | SEC↗ |
| GILEAD SCIENCES, INC. | 10% Owner | X Exercise deriv | 2025-11-26 | 2025-12-01 | 13,335,000 | $0.75 | $10.00M | 36,645,266 | SEC↗ |
| GILEAD SCIENCES, INC. | 10% Owner | X Exercise deriv | 2025-11-26 | 2025-12-01 | 13,335,000 | — | $0 | 0 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | A Award deriv | 2025-11-21 | 2025-11-25 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | D To issuer deriv | 2025-11-21 | 2025-11-25 | 700,000 | — | $0 | 0 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | A Award deriv | 2025-11-21 | 2025-11-25 | 700,000 | — | $0 | 700,000 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | D To issuer deriv | 2025-11-21 | 2025-11-25 | 350,000 | — | $0 | 0 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | A Award deriv | 2025-11-21 | 2025-11-25 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | D To issuer deriv | 2025-11-21 | 2025-11-25 | 100,000 | — | $0 | 0 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | A Award deriv | 2025-11-21 | 2025-11-25 | 50,041 | — | $0 | 50,041 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | D To issuer deriv | 2025-11-21 | 2025-11-25 | 50,041 | — | $0 | 0 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | A Award deriv | 2025-11-21 | 2025-11-25 | 135,134 | — | $0 | 135,134 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | D To issuer deriv | 2025-11-21 | 2025-11-25 | 135,134 | — | $0 | 0 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | A Award deriv | 2025-11-21 | 2025-11-25 | 473,334 | — | $0 | 473,334 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | A Award deriv | 2025-11-21 | 2025-11-25 | 2,075,000 | — | $0 | 2,075,000 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | D To issuer deriv | 2025-11-21 | 2025-11-25 | 239,703 | — | $0 | 0 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | A Award deriv | 2025-11-21 | 2025-11-25 | 239,703 | — | $0 | 239,703 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | D To issuer deriv | 2025-11-21 | 2025-11-25 | 473,334 | — | $0 | 0 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | A Award deriv | 2025-11-21 | 2025-11-25 | 350,000 | — | $0 | 350,000 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | D To issuer deriv | 2025-11-21 | 2025-11-25 | 150,000 | — | $0 | 0 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | A Award deriv | 2025-11-21 | 2025-11-25 | 37,296 | — | $0 | 37,296 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | D To issuer deriv | 2025-11-21 | 2025-11-25 | 37,296 | — | $0 | 0 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | A Award deriv | 2025-11-21 | 2025-11-25 | 45,000 | — | $0 | 45,000 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | D To issuer deriv | 2025-11-21 | 2025-11-25 | 20,000 | — | $0 | 0 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | A Award deriv | 2025-11-21 | 2025-11-25 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | D To issuer deriv | 2025-11-21 | 2025-11-25 | 117,000 | — | $0 | 0 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | A Award deriv | 2025-11-21 | 2025-11-25 | 117,000 | — | $0 | 117,000 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | D To issuer deriv | 2025-11-21 | 2025-11-25 | 150,000 | — | $0 | 0 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | A Award deriv | 2025-11-21 | 2025-11-25 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | D To issuer deriv | 2025-11-21 | 2025-11-25 | 300,000 | — | $0 | 0 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | A Award deriv | 2025-11-21 | 2025-11-25 | 300,000 | — | $0 | 300,000 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | A Award deriv | 2025-11-21 | 2025-11-25 | 925,000 | — | $0 | 925,000 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | D To issuer deriv | 2025-11-21 | 2025-11-25 | 155,090 | — | $0 | 0 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | A Award deriv | 2025-11-21 | 2025-11-25 | 155,090 | — | $0 | 155,090 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | D To issuer deriv | 2025-11-21 | 2025-11-25 | 23,786 | — | $0 | 0 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | A Award deriv | 2025-11-21 | 2025-11-25 | 23,786 | — | $0 | 23,786 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | D To issuer deriv | 2025-11-21 | 2025-11-25 | 45,000 | — | $0 | 0 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | A Award deriv | 2025-11-21 | 2025-11-25 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | A Award deriv | 2025-11-21 | 2025-11-25 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | D To issuer deriv | 2025-11-21 | 2025-11-25 | 35,000 | — | $0 | 0 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | A Award deriv | 2025-11-21 | 2025-11-25 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | D To issuer deriv | 2025-11-21 | 2025-11-25 | 25,000 | — | $0 | 0 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | D To issuer deriv | 2025-11-21 | 2025-11-25 | 15,000 | — | $0 | 0 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | D To issuer deriv | 2025-11-21 | 2025-11-25 | 106,000 | — | $0 | 0 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | A Award deriv | 2025-11-21 | 2025-11-25 | 625,000 | — | $0 | 625,000 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | D To issuer deriv | 2025-11-21 | 2025-11-25 | 44,210 | — | $0 | 0 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | A Award deriv | 2025-11-21 | 2025-11-25 | 44,210 | — | $0 | 44,210 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | A Award deriv | 2025-11-21 | 2025-11-25 | 106,000 | — | $0 | 106,000 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A Award deriv | 2025-11-21 | 2025-11-25 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | D To issuer deriv | 2025-11-21 | 2025-11-25 | 20,000 | — | $0 | 0 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A Award deriv | 2025-11-21 | 2025-11-25 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | D To issuer deriv | 2025-11-21 | 2025-11-25 | 25,000 | — | $0 | 0 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A Award deriv | 2025-11-21 | 2025-11-25 | 55,000 | — | $0 | 55,000 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | D To issuer deriv | 2025-11-21 | 2025-11-25 | 55,000 | — | $0 | 0 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A Award deriv | 2025-11-21 | 2025-11-25 | 131,700 | — | $0 | 131,700 | SEC↗ |
| Shannon James Samuel | Director | P Buy | 2025-06-17 | 2025-06-18 | 25,000 | $0.69 | $17.3K | 70,000 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | P Buy | 2025-06-16 | 2025-06-18 | 36,289 | $0.68 | $24.7K | 281,172 | SEC↗ |
| Shannon James Samuel | Director | P Buy | 2025-06-16 | 2025-06-18 | 45,000 | $0.69 | $31.0K | 45,000 | SEC↗ |
| Rossi Christina | Director | A Award deriv | 2025-06-11 | 2025-06-12 | 31,000 | — | $0 | 31,000 | SEC↗ |
| Shannon James Samuel | Director | A Award deriv | 2025-06-11 | 2025-06-12 | 31,000 | — | $0 | 31,000 | SEC↗ |
| Xu Yuan | Director | A Award deriv | 2025-06-11 | 2025-06-12 | 31,000 | — | $0 | 31,000 | SEC↗ |
| Clancy Paul J | Director | A Award deriv | 2025-06-11 | 2025-06-12 | 31,000 | — | $0 | 31,000 | SEC↗ |
| Curran Daniel J. | Director | A Award deriv | 2025-06-11 | 2025-06-12 | 31,000 | — | $0 | 31,000 | SEC↗ |
| Bonstein Sara | Director | A Award deriv | 2025-06-11 | 2025-06-12 | 31,000 | — | $0 | 31,000 | SEC↗ |
| Brennan Aoife | Director | A Award deriv | 2025-06-11 | 2025-06-12 | 31,000 | — | $0 | 31,000 | SEC↗ |
| ROSS ROBERT W. | Director | A Award deriv | 2025-06-11 | 2025-06-12 | 31,000 | — | $0 | 31,000 | SEC↗ |
| Bello Akintunde Olatokumbo | Director | A Award deriv | 2025-06-10 | 2025-06-12 | 62,000 | — | $0 | 62,000 | SEC↗ |
| GILEAD SCIENCES, INC. | 10% Owner | P Buy deriv | 2025-06-05 | 2025-06-06 | 13,335,000 | — | $0 | 13,335,000 | SEC↗ |
| GILEAD SCIENCES, INC. | 10% Owner | P Buy deriv | 2025-06-05 | 2025-06-06 | 13,335,000 | — | $0 | 13,335,000 | SEC↗ |
| GILEAD SCIENCES, INC. | 10% Owner | P Buy deriv | 2025-06-05 | 2025-06-06 | 13,335,000 | — | $0 | 23,310,266 | SEC↗ |
| GILEAD SCIENCES, INC. | 10% Owner | P Buy deriv | 2025-06-05 | 2025-06-06 | 13,335,000 | — | $0 | 13,335,000 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | A Award deriv | 2025-04-15 | 2025-04-16 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | A Award deriv | 2025-04-15 | 2025-04-16 | 190,000 | — | $0 | 190,000 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | S Sale | 2025-01-02 | 2025-01-03 | 1,803 | $0.98 | $1.8K | 3,197 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | S Sale | 2025-01-02 | 2025-01-03 | 6,954 | $0.98 | $6.8K | 12,421 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A Award deriv | 2025-01-01 | 2025-01-03 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | M Exercise deriv | 2025-01-01 | 2025-01-03 | 5,000 | — | $0 | 15,000 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | A Award deriv | 2025-01-01 | 2025-01-03 | 638,000 | — | $0 | 638,000 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | M Exercise deriv | 2025-01-01 | 2025-01-03 | 44,250 | — | $0 | 132,750 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | A Award deriv | 2025-01-01 | 2025-01-03 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | M Exercise deriv | 2025-01-01 | 2025-01-03 | 16,625 | — | $0 | 49,875 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | M Exercise deriv | 2025-01-01 | 2025-01-03 | 19,375 | — | $0 | 58,125 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | A Award deriv | 2025-01-01 | 2025-01-03 | 251,000 | — | $0 | 251,000 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | M Exercise | 2025-01-01 | 2025-01-03 | 5,000 | — | $0 | 5,000 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | M Exercise | 2025-01-01 | 2025-01-03 | 44,250 | — | $0 | 244,883 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | M Exercise | 2025-01-01 | 2025-01-03 | 16,625 | — | $0 | 16,625 | SEC↗ |
| Frankenfield Christopher James | Chief Financial Officer | M Exercise | 2025-01-01 | 2025-01-03 | 19,375 | — | $0 | 19,375 | SEC↗ |
| GILEAD SCIENCES, INC. | 10% Owner | P Buy deriv | 2024-12-18 | 2024-12-19 | 6,092,816 | $1.04 | $6.34M | 9,975,266 | SEC↗ |
| GILEAD SCIENCES, INC. | 10% Owner | P Buy | 2024-12-18 | 2024-12-19 | 1,759,978 | $1.04 | $1.83M | 9,105,451 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A Award deriv | 2024-10-01 | 2024-10-02 | 26,000 | — | $0 | 26,000 | SEC↗ |
| Frankenfield Christopher James | Chief Operating Officer | A Award deriv | 2024-08-03 | 2024-08-06 | 52,000 | — | $0 | 52,000 | SEC↗ |
| Curran Daniel J. | Director | A Award deriv | 2024-06-14 | 2024-06-17 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Clancy Paul J | Director | A Award deriv | 2024-06-14 | 2024-06-17 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Rossi Christina | Director | A Award deriv | 2024-06-14 | 2024-06-17 | 25,000 | — | $0 | 25,000 | SEC↗ |
| ROSS ROBERT W. | Director | A Award deriv | 2024-06-14 | 2024-06-17 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Bonstein Sara | Director | A Award deriv | 2024-06-14 | 2024-06-17 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Xu Yuan | Director | A Award deriv | 2024-06-14 | 2024-06-17 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Brennan Aoife | Director | A Award deriv | 2024-06-13 | 2024-06-17 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Shannon James Samuel | Director | A Award deriv | 2024-06-13 | 2024-06-17 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | A Award deriv | 2024-05-01 | 2024-05-03 | 474,000 | — | $0 | 474,000 | SEC↗ |
| Frankenfield Christopher James | CHIEF OPERATING OFFICER | A Award deriv | 2024-05-01 | 2024-05-03 | 208,000 | — | $0 | 208,000 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | A Award deriv | 2024-05-01 | 2024-05-03 | 59,333 | — | $0 | 59,333 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A Award deriv | 2024-05-01 | 2024-05-03 | 20,000 | — | $0 | 20,000 | SEC↗ |
| GILEAD SCIENCES, INC. | 10% Owner | P Buy deriv | 2024-04-02 | 2024-04-03 | 3,882,450 | $0.76 | $2.95M | 3,882,450 | SEC↗ |
| GILEAD SCIENCES, INC. | 10% Owner | P Buy | 2024-04-02 | 2024-04-03 | 485,250 | $0.76 | $368.8K | 7,345,473 | SEC↗ |
| Atlas Venture Fund XI, L.P. | 10% Owner | S Sale | 2024-02-08 | 2024-02-09 | 733 | $0.64 | $469 | 2,019,563 | SEC↗ |
| Atlas Venture Fund XI, L.P. | 10% Owner | S Sale | 2024-02-08 | 2024-02-09 | 267 | $0.64 | $171 | 734,546 | SEC↗ |
| Atlas Venture Associates Oppor | 10% Owner | S Sale | 2024-01-12 | 2024-01-16 | 1,540 | $0.83 | $1.3K | 2,020,296 | SEC↗ |
| Atlas Venture Associates Oppor | 10% Owner | S Sale | 2024-01-12 | 2024-01-16 | 560 | $0.83 | $465 | 734,813 | SEC↗ |
| Atlas Venture Associates Oppor | 10% Owner | S Sale | 2024-01-11 | 2024-01-16 | 569 | $0.87 | $495 | 735,373 | SEC↗ |
| Atlas Venture Associates Oppor | 10% Owner | S Sale | 2024-01-11 | 2024-01-16 | 1,566 | $0.87 | $1.4K | 2,021,836 | SEC↗ |
| Russo Rene | PRESIDENT AND CEO | A Award deriv | 2024-01-01 | 2024-01-03 | 177,000 | — | $0 | 177,000 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A Award deriv | 2024-01-01 | 2024-01-03 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Luptakova Katarina | CHIEF MEDICAL OFFICER | A Award deriv | 2024-01-01 | 2024-01-03 | 66,500 | — | $0 | 66,500 | SEC↗ |
| Frankenfield Christopher James | CHIEF OPERATING OFFICER | A Award deriv | 2024-01-01 | 2024-01-03 | 77,500 | — | $0 | 77,500 | SEC↗ |
| Luptakova Katarina | Chief Medical Officer | A Award deriv | 2023-09-05 | 2023-09-07 | 106,000 | — | $0 | 106,000 | SEC↗ |
| Huber Martin H. Jr. | PRESIDENT AND HEAD OF R&D | A Award deriv | 2023-08-16 | 2023-08-18 | 136,500 | — | $0 | 136,500 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A Award deriv | 2023-08-16 | 2023-08-18 | 25,000 | — | $0 | 25,000 | SEC↗ |
| Frankenfield Christopher James | CHIEF OPERATING OFFICER | A Award deriv | 2023-08-16 | 2023-08-18 | 300,000 | — | $0 | 300,000 | SEC↗ |
| Russo Rene | CEO | A Award deriv | 2023-08-16 | 2023-08-18 | 700,000 | — | $0 | 700,000 | SEC↗ |
| Frankenfield Christopher James | Chief Operating Officer | A Award deriv | 2023-08-03 | 2023-08-07 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Rossi Christina | Director | A Award deriv | 2023-06-12 | 2023-06-13 | 13,200 | — | $0 | 13,200 | SEC↗ |
| Clancy Paul J | Director | A Award deriv | 2023-06-12 | 2023-06-13 | 13,200 | — | $0 | 13,200 | SEC↗ |
| Bonstein Sara | Director | A Award deriv | 2023-06-12 | 2023-06-13 | 13,200 | — | $0 | 13,200 | SEC↗ |
| Heyman Tomas J. | Director | A Award deriv | 2023-06-12 | 2023-06-13 | 13,200 | — | $0 | 13,200 | SEC↗ |
| ROSS ROBERT W. | Director | A Award deriv | 2023-06-12 | 2023-06-13 | 13,200 | — | $0 | 13,200 | SEC↗ |
| Xu Yuan | Director | A Award deriv | 2023-06-12 | 2023-06-13 | 13,200 | — | $0 | 13,200 | SEC↗ |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING | A Award deriv | 2023-04-01 | 2023-04-03 | 55,000 | — | $0 | 55,000 | SEC↗ |
| English Edward C | PRINCIPAL ACCOUNTING OFFICER | A Award deriv | 2023-01-01 | 2023-01-04 | 24,000 | — | $0 | 24,000 | SEC↗ |
| Huber Martin H. Jr. | PRESIDENT AND HEAD OF R&D | A Award deriv | 2023-01-01 | 2023-01-04 | 136,500 | — | $0 | 136,500 | SEC↗ |
| Russo Rene | CEO | A Award deriv | 2023-01-01 | 2023-01-04 | 350,000 | — | $0 | 350,000 | SEC↗ |
| Heyman Tomas J. | Director | A Award deriv | 2022-09-15 | 2022-09-16 | 26,400 | — | $0 | 26,400 | SEC↗ |
| ROSS ROBERT W. | Director | A Award deriv | 2022-06-15 | 2022-06-17 | 26,400 | — | $0 | 26,400 | SEC↗ |
| Bonstein Sara | Director | A Award deriv | 2022-06-15 | 2022-06-17 | 13,200 | — | $0 | 13,200 | SEC↗ |
| Xu Yuan | Director | A Award deriv | 2022-06-15 | 2022-06-17 | 13,200 | — | $0 | 13,200 | SEC↗ |
| Clancy Paul J | Director | A Award deriv | 2022-06-15 | 2022-06-17 | 13,200 | — | $0 | 13,200 | SEC↗ |
| Rossi Christina | Director | A Award deriv | 2022-06-15 | 2022-06-17 | 13,200 | — | $0 | 13,200 | SEC↗ |
| Ross Michael Jay | Director | A Award deriv | 2022-06-15 | 2022-06-17 | 13,200 | — | $0 | 13,200 | SEC↗ |
| Huber Martin H. Jr. | PRESIDENT AND HEAD OF R&D | A Award deriv | 2022-06-15 | 2022-06-17 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Huber Martin H. Jr. | PRESIDENT AND HEAD OF R&D | A Award deriv | 2022-06-15 | 2022-06-23 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Russo Rene | CEO AND PRESIDENT | A Award deriv | 2022-02-22 | 2022-02-24 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Huber Martin H. Jr. | PRESIDENT OF R&D AND CMO | A Award deriv | 2022-02-22 | 2022-02-24 | 65,000 | — | $0 | 65,000 | SEC↗ |
| Giovine Salvatore | CHIEF FINANCIAL OFFICER | A Award deriv | 2022-02-22 | 2022-02-24 | 49,500 | — | $0 | 49,500 | SEC↗ |
| Xu Yuan | Director | A Award deriv | 2022-01-04 | 2022-01-06 | 26,400 | — | $0 | 26,400 | SEC↗ |
| Russo Rene | CEO AND PRESIDENT | A Award deriv | 2021-12-22 | 2022-01-04 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Russo Rene | CEO AND PRESIDENT | A Award deriv | 2021-12-22 | 2021-12-23 | 100,000 | — | $0 | 100,000 | SEC↗ |
| BCIP Life Sciences Associates, | 10% Owner | P Buy | 2021-12-10 | 2021-12-10 | 21,812 | $9.56 | $208.5K | 2,802,225 | SEC↗ |
| BCIP Life Sciences Associates, | 10% Owner | P Buy | 2021-12-10 | 2021-12-10 | 3,188 | $10.24 | $32.6K | 2,805,413 | SEC↗ |
| BCIP Life Sciences Associates, | 10% Owner | P Buy | 2021-12-09 | 2021-12-10 | 4,011 | $9.84 | $39.5K | 2,780,413 | SEC↗ |
| BCIP Life Sciences Associates, | 10% Owner | P Buy | 2021-12-08 | 2021-12-10 | 13,458 | $9.62 | $129.5K | 2,776,402 | SEC↗ |
| Alexandria Venture Investments | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-26 | 1,581,026 | — | $0 | 0 | SEC↗ |
| Clancy Paul J | Director | A Award deriv | 2021-10-26 | 2021-10-26 | 44,033 | — | $0 | 44,033 | SEC↗ |
| Clancy Paul J | Director | A Award deriv | 2021-10-26 | 2021-10-26 | 65,528 | — | $0 | 65,528 | SEC↗ |
| Atlas Venture Opportunity Fund | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-26 | 13,043,477 | — | $0 | 0 | SEC↗ |
| Atlas Venture Opportunity Fund | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-26 | 5,210,204 | — | $0 | 0 | SEC↗ |
| Atlas Venture Opportunity Fund | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-26 | 5,928,852 | — | $0 | 0 | SEC↗ |
| BAY CITY CAPITAL LLC | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-26 | 6,324,110 | — | $0 | 0 | SEC↗ |
| BAY CITY CAPITAL LLC | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-26 | 1,437,297 | — | $0 | 0 | SEC↗ |
| Merck KGaA | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-26 | 3,952,568 | — | $0 | 0 | SEC↗ |
| Merck KGaA | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-26 | 2,515,271 | — | $0 | 0 | SEC↗ |
| Rock Springs Capital Master Fu | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-26 | 1,437,297 | — | $0 | 0 | SEC↗ |
| Rock Springs Capital Master Fu | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-26 | 7,186,490 | — | $0 | 0 | SEC↗ |
| RiverVest Venture Fund IV, L.P | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-26 | 359,324 | — | $0 | 0 | SEC↗ |
| RiverVest Venture Fund IV, L.P | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-26 | 832,120 | — | $0 | 0 | SEC↗ |
| Takeda Ventures, Inc. | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-26 | 1,248,180 | — | $0 | 0 | SEC↗ |
| Takeda Ventures, Inc. | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-26 | 226,941 | — | $0 | 0 | SEC↗ |
| SV7 (IMF) GP LLP | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-28 | 2,874,595 | — | $0 | 0 | SEC↗ |
| SV7 (IMF) GP LLP | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-28 | 9,486,166 | — | $0 | 0 | SEC↗ |
| SV7 (IMF) GP LLP | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-28 | 2,874,595 | — | $0 | 0 | SEC↗ |
| SV7 (IMF) GP LLP | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-28 | 9,486,166 | — | $0 | 0 | SEC↗ |
| FMR LLC | Other | C Conversion deriv | 2021-10-26 | 2021-10-28 | 7,500,000 | — | $0 | 0 | SEC↗ |
| FMR LLC | Other | C Conversion deriv | 2021-10-26 | 2021-10-28 | 6,521,739 | — | $0 | 0 | SEC↗ |
| FMR LLC | Other | C Conversion deriv | 2021-10-26 | 2021-10-28 | 272,687 | — | $0 | 0 | SEC↗ |
| FMR LLC | Other | C Conversion deriv | 2021-10-26 | 2021-10-28 | 3,536,046 | — | $0 | 0 | SEC↗ |
| FMR LLC | Other | C Conversion deriv | 2021-10-26 | 2021-10-28 | 42,421 | — | $0 | 0 | SEC↗ |
| FIL Ltd | Other | C Conversion deriv | 2021-10-26 | 2021-10-28 | 2,077,698 | — | $0 | 0 | SEC↗ |
| Deerfield Mgmt L.P. | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-28 | 7,186,489 | — | $0 | 0 | SEC↗ |
| Deerfield Mgmt L.P. | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-10-28 | 7,186,489 | — | $0 | 0 | SEC↗ |
| SV7 Impact Medicine Fund LP | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-11-03 | 9,486,166 | — | $0 | 0 | SEC↗ |
| SV7 Impact Medicine Fund LP | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-11-03 | 2,874,595 | — | $0 | 0 | SEC↗ |
| SV7 Impact Medicine Fund LP | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-11-03 | 2,874,595 | — | $0 | 0 | SEC↗ |
| SV7 Impact Medicine Fund LP | 10% Owner | C Conversion deriv | 2021-10-26 | 2021-11-03 | 9,486,166 | — | $0 | 0 | SEC↗ |
| Alexandria Venture Investments | 10% Owner | C Conversion | 2021-10-26 | 2021-10-26 | 166,423 | — | $0 | 166,423 | SEC↗ |
| Atlas Venture Opportunity Fund | 10% Owner | P Buy | 2021-10-26 | 2021-10-26 | 187,500 | $16.00 | $3.00M | 735,942 | SEC↗ |
| Atlas Venture Opportunity Fund | 10% Owner | C Conversion | 2021-10-26 | 2021-10-26 | 1,372,998 | — | $0 | 1,399,313 | SEC↗ |
| Atlas Venture Opportunity Fund | 10% Owner | C Conversion | 2021-10-26 | 2021-10-26 | 624,089 | — | $0 | 2,023,402 | SEC↗ |
| Atlas Venture Opportunity Fund | 10% Owner | C Conversion | 2021-10-26 | 2021-10-26 | 548,442 | — | $0 | 548,442 | SEC↗ |
| BAY CITY CAPITAL LLC | 10% Owner | P Buy | 2021-10-26 | 2021-10-26 | 312,500 | $16.00 | $5.00M | 1,129,490 | SEC↗ |
| BAY CITY CAPITAL LLC | 10% Owner | C Conversion | 2021-10-26 | 2021-10-26 | 665,696 | — | $0 | 665,696 | SEC↗ |
| BAY CITY CAPITAL LLC | 10% Owner | C Conversion | 2021-10-26 | 2021-10-26 | 151,294 | — | $0 | 816,990 | SEC↗ |
| Merck KGaA | 10% Owner | C Conversion | 2021-10-26 | 2021-10-26 | 416,060 | — | $0 | 416,060 | SEC↗ |
| Merck KGaA | 10% Owner | C Conversion | 2021-10-26 | 2021-10-26 | 264,765 | — | $0 | 680,825 | SEC↗ |
| Rock Springs Capital Master Fu | 10% Owner | C Conversion | 2021-10-26 | 2021-10-26 | 756,472 | — | $0 | 756,472 | SEC↗ |
| Rock Springs Capital Master Fu | 10% Owner | C Conversion | 2021-10-26 | 2021-10-26 | 151,294 | — | $0 | 151,294 | SEC↗ |
| Rock Springs Capital Master Fu | 10% Owner | P Buy | 2021-10-26 | 2021-10-26 | 500,000 | $16.00 | $8.00M | 1,256,472 | SEC↗ |
| RiverVest Venture Fund IV, L.P | 10% Owner | P Buy | 2021-10-26 | 2021-10-26 | 250,000 | $16.00 | $4.00M | 1,441,444 | SEC↗ |
| RiverVest Venture Fund IV, L.P | 10% Owner | C Conversion | 2021-10-26 | 2021-10-26 | 832,120 | — | $0 | 832,120 | SEC↗ |
| RiverVest Venture Fund IV, L.P | 10% Owner | C Conversion | 2021-10-26 | 2021-10-26 | 359,324 | — | $0 | 1,191,444 | SEC↗ |
| Takeda Ventures, Inc. | 10% Owner | C Conversion | 2021-10-26 | 2021-10-26 | 1,475,121 | — | $0 | 1,475,121 | SEC↗ |
| SV7 (IMF) GP LLP | 10% Owner | C Conversion | 2021-10-26 | 2021-10-28 | 302,588 | — | $0 | 1,301,132 | SEC↗ |
| SV7 (IMF) GP LLP | 10% Owner | C Conversion | 2021-10-26 | 2021-10-28 | 302,588 | — | $0 | 1,301,132 | SEC↗ |
| SV7 (IMF) GP LLP | 10% Owner | C Conversion | 2021-10-26 | 2021-10-28 | 998,544 | — | $0 | 998,544 | SEC↗ |
| SV7 (IMF) GP LLP | 10% Owner | C Conversion | 2021-10-26 | 2021-10-28 | 998,544 | — | $0 | 998,544 | SEC↗ |
| FMR LLC | Other | C Conversion | 2021-10-26 | 2021-10-28 | 789,473 | — | $0 | 815,788 | SEC↗ |
| FMR LLC | Other | C Conversion | 2021-10-26 | 2021-10-28 | 372,215 | — | $0 | 372,215 | SEC↗ |
| FMR LLC | Other | C Conversion | 2021-10-26 | 2021-10-28 | 28,703 | — | $0 | 1,530,990 | SEC↗ |
| FMR LLC | Other | C Conversion | 2021-10-26 | 2021-10-28 | 686,499 | — | $0 | 1,502,287 | SEC↗ |
| FMR LLC | Other | C Conversion | 2021-10-26 | 2021-10-28 | 4,465 | — | $0 | 4,465 | SEC↗ |
| FIL Ltd | Other | C Conversion | 2021-10-26 | 2021-10-28 | 218,705 | — | $0 | 218,705 | SEC↗ |
| Deerfield Mgmt L.P. | 10% Owner | C Conversion | 2021-10-26 | 2021-10-28 | 756,472 | — | $0 | 756,472 | SEC↗ |
| Deerfield Mgmt L.P. | 10% Owner | C Conversion | 2021-10-26 | 2021-10-28 | 756,472 | — | $0 | 756,472 | SEC↗ |
| Deerfield Mgmt L.P. | 10% Owner | P Buy | 2021-10-26 | 2021-10-28 | 387,500 | $16.00 | $6.20M | 1,143,972 | SEC↗ |
| Deerfield Mgmt L.P. | 10% Owner | P Buy | 2021-10-26 | 2021-10-28 | 387,500 | $16.00 | $6.20M | 1,143,972 | SEC↗ |
| SV7 Impact Medicine Fund LP | 10% Owner | P Buy | 2021-10-26 | 2021-11-03 | 312,500 | $16.00 | $5.00M | 1,613,632 | SEC↗ |
| SV7 Impact Medicine Fund LP | 10% Owner | P Buy | 2021-10-26 | 2021-11-03 | 312,500 | $16.00 | $5.00M | 1,613,632 | SEC↗ |
| SV7 Impact Medicine Fund LP | 10% Owner | C Conversion | 2021-10-26 | 2021-11-03 | 302,588 | — | $0 | 1,301,132 | SEC↗ |
| SV7 Impact Medicine Fund LP | 10% Owner | C Conversion | 2021-10-26 | 2021-11-03 | 302,588 | — | $0 | 1,301,132 | SEC↗ |
| SV7 Impact Medicine Fund LP | 10% Owner | C Conversion | 2021-10-26 | 2021-11-03 | 998,544 | — | $0 | 998,544 | SEC↗ |
| SV7 Impact Medicine Fund LP | 10% Owner | C Conversion | 2021-10-26 | 2021-11-03 | 998,544 | — | $0 | 998,544 | SEC↗ |
| Giovine Salvatore | Chief Financial Officer | A Award deriv | 2021-10-21 | 2021-10-25 | 28,755 | — | $0 | 28,755 | SEC↗ |
| Huber Martin H. Jr. | President of R&D and CMO | A Award deriv | 2021-10-21 | 2021-10-25 | 157,058 | — | $0 | 157,058 | SEC↗ |
| Ross Michael Jay | Director | A Award deriv | 2021-10-21 | 2021-10-25 | 26,400 | — | $0 | 26,400 | SEC↗ |
| Russo Rene | CEO and President | A Award deriv | 2021-10-21 | 2021-10-25 | 50,041 | — | $0 | 50,041 | SEC↗ |